Alzheimer’s Researchers Identify Biomarkers of Response to Anavex 2-73 Treatment

Alzheimer’s Researchers Identify Biomarkers of Response to Anavex 2-73 Treatment
Researchers have identified two biomarkers that could help determine which Alzheimer’s disease patients can benefit from Anavex 2-73 treatment. The results were reported at the 2018 Alzheimer’s Association International Conference (AAIC) in Chicago. The study, “Systematic Processing of Full Genomic Analysis of ANAVEX®2-73 Phase 2a Alzheimer’s Disease Study Identifies Biomarkers Enabling a Precision Medicine Approach,” was presented by Harald Hampel, the study’s first author and AXA Research Fund and Sorbonne University Excellence Chair at Sorbonne University in Paris. Anavex 2-73, developed by Anavex Life Sciences, is an investigational therapy with the potential to modify the course of Alzheimer’s disease instead of acting on symptoms alone. It binds to and activates the Sigma-1 receptor (SIGMAR1), known to have neuroprotective effects, resulting in reduced neuroinflammation, accumulation of beta amyloid and tau proteins, and oxidative stress. All are involved in Alzheimer’s disease and other neurodegenerative disorders.
Subscribe or to access all post and page content.